{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:19:56Z","timestamp":1789769996638,"version":"4.0.1"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences, Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.metabol.2020.154291","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T21:23:10Z","timestamp":1591737790000},"page":"154291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"S","title":["Changing trends of liver transplantation and mortality from non-alcoholic fatty liver disease"],"prefix":"10.1016","volume":"111","author":[{"given":"Avik","family":"Majumdar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel A.","family":"Tsochatzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2020.154291_bb0005","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/liv.13682","article-title":"Liver diseases: a major, neglected global public health problem requiring urgent actions and large-scale screening","volume":"38","author":"Marcellin","year":"2018","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.metabol.2020.154291_bb0010","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world","volume":"70","author":"Asrani","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2020.154291_bb0015","series-title":"Australia and New Zealand liver transplant Registry Brisbane","author":"Registry Report ANZLTR","year":"2017"},{"issue":"6","key":"10.1016\/j.metabol.2020.154291_bb0020","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.25762","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association","volume":"55","author":"Chalasani","year":"2012","journal-title":"Hepatology."},{"issue":"2","key":"10.1016\/j.metabol.2020.154291_bb0025","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with Long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology."},{"issue":"5","key":"10.1016\/j.metabol.2020.154291_bb0030","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology."},{"issue":"6","key":"10.1016\/j.metabol.2020.154291_bb0035","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Hagstrom","year":"2017","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.metabol.2020.154291_bb0040","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology."},{"key":"10.1016\/j.metabol.2020.154291_bb0045","series-title":"What\u2019s in a name?","author":"Fouad","year":"2020"},{"issue":"8","key":"10.1016\/j.metabol.2020.154291_bb0050","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1053\/j.gastro.2016.03.005","article-title":"Contribution of alcoholic and nonalcoholic fatty liver disease to the burden of liver-related morbidity and mortality","volume":"150","author":"Younossi","year":"2016","journal-title":"Gastroenterology."},{"issue":"1","key":"10.1016\/j.metabol.2020.154291_bb0055","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","article-title":"The natural history of nonalcoholic fatty liver disease: a population-based cohort study","volume":"129","author":"Adams","year":"2005","journal-title":"Gastroenterology."},{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2020.154291_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jgh.14270","article-title":"Burden of non-alcoholic fatty liver disease in Australia","volume":"33","author":"Mahady","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.metabol.2020.154291_bb0065","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.metabol.2020.154291_bb0070","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jhep.2016.04.005","article-title":"Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications","volume":"65","author":"Francque","year":"2016","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.metabol.2020.154291_bb0075","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.cgh.2018.05.057","article-title":"Nonalcoholic Steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.metabol.2020.154291_bb0080","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41395-018-0088-6","article-title":"NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances","volume":"113","author":"Noureddin","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.metabol.2020.154291_bb0085","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","article-title":"Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States","volume":"148","author":"Wong","year":"2015","journal-title":"Gastroenterology."},{"issue":"2","key":"10.1016\/j.metabol.2020.154291_bb0090","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jhep.2019.04.011","article-title":"Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European liver transplant Registry study","volume":"71","author":"Haldar","year":"2019","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.metabol.2020.154291_bb0095","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/lt.25361","article-title":"Increasing incidence of nonalcoholic Steatohepatitis as an indication for liver transplantation in Australia and New Zealand","volume":"25","author":"Calzadilla-Bertot","year":"2019","journal-title":"Liver Transpl"},{"issue":"1","key":"10.1016\/j.metabol.2020.154291_bb0100","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/TP.0000000000002433","article-title":"International liver transplantation consensus statement on end-stage liver disease due to nonalcoholic Steatohepatitis and liver transplantation","volume":"103","author":"Tsochatzis","year":"2019","journal-title":"Transplantation."},{"issue":"1","key":"10.1016\/j.metabol.2020.154291_bb0105","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology."},{"issue":"1","key":"10.1016\/j.metabol.2020.154291_bb0110","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.metabol.2020.154291_bb0115","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology."},{"issue":"3","key":"10.1016\/j.metabol.2020.154291_bb0120","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease - a global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2020.154291_bb0125","doi-asserted-by":"crossref","DOI":"10.1111\/jgh.15009","article-title":"Nonalcoholic fatty liver disease burden: Australia, 2019-2030","author":"Adams","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.metabol.2020.154291_bb0130","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/hep.30626","article-title":"Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps","volume":"70","author":"Lonardo","year":"2019","journal-title":"Hepatology."},{"issue":"2","key":"10.1016\/j.metabol.2020.154291_bb0135","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","article-title":"Aller-de la Fuente R, Metwally M, et al. fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study","volume":"155","author":"Vilar-Gomez","year":"2018","journal-title":"Gastroenterology."},{"issue":"8","key":"10.1016\/j.metabol.2020.154291_bb0140","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/liv.13709","article-title":"A simple clinical model predicts incident hepatic steatosis in a community-based cohort: the Framingham heart study","volume":"38","author":"Long","year":"2018","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.metabol.2020.154291_bb0145","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/gutjnl-2011-300342","article-title":"Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography","volume":"61","author":"Wong","year":"2012","journal-title":"Gut."},{"issue":"1","key":"10.1016\/j.metabol.2020.154291_bb0150","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/lt.22435","article-title":"Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States","volume":"18","author":"Afzali","year":"2012","journal-title":"Liver Transpl"},{"issue":"1","key":"10.1016\/j.metabol.2020.154291_bb0155","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1365-2265.2006.02543.x","article-title":"Effects of HRT on liver enzyme levels in women with type 2 diabetes: a randomized placebo-controlled trial","volume":"65","author":"McKenzie","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"10.1016\/j.metabol.2020.154291_bb0160","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.28785","article-title":"The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology."},{"issue":"2","key":"10.1016\/j.metabol.2020.154291_bb0165","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jhep.2017.11.012","article-title":"Determinants of fibrosis progression and regression in NASH","volume":"68","author":"Schuppan","year":"2018","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.metabol.2020.154291_bb0170","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism."},{"issue":"2","key":"10.1016\/j.metabol.2020.154291_bb0175","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","article-title":"Genetics and epigenetics of NAFLD and NASH: clinical impact","volume":"68","author":"Eslam","year":"2018","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.metabol.2020.154291_bb0180","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1053\/j.gastro.2016.01.037","article-title":"Genetic factors that affect risk of alcoholic and nonalcoholic fatty liver disease","volume":"150","author":"Anstee","year":"2016","journal-title":"Gastroenterology."},{"issue":"5","key":"10.1016\/j.metabol.2020.154291_bb0185","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","article-title":"Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management","volume":"62","author":"McPherson","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2020.154291_bb0190","doi-asserted-by":"crossref","unstructured":"Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643\u201354 e1\u20139; quiz e39\u201340.","DOI":"10.1016\/j.cgh.2014.04.014"},{"issue":"6","key":"10.1016\/j.metabol.2020.154291_bb0195","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/hep.30664","article-title":"The natural history of advanced fibrosis due to nonalcoholic Steatohepatitis: data from the Simtuzumab trials","volume":"70","author":"Sanyal","year":"2019","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2020.154291_bb0200","first-page":"244A","article-title":"Hepatic venous pressure gradient (HVPG) predicts clinical disease progression in patients with compensated cirrhosis due to NASH","volume":"66","author":"Bosch","year":"2017","journal-title":"Hepatology."},{"issue":"2","key":"10.1016\/j.metabol.2020.154291_bb0205","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/jhep.2003.50320","article-title":"Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C","volume":"38","author":"Hui","year":"2003","journal-title":"Hepatology."},{"issue":"9","key":"10.1016\/j.metabol.2020.154291_bb0210","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/apt.15219","article-title":"Collagen proportionate area is an independent predictor of long-term outcome in patients with non-alcoholic fatty liver disease","volume":"49","author":"Buzzetti","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.metabol.2020.154291_bb0215","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.12565","article-title":"Association of Histologic Disease Activity with Progression of nonalcoholic fatty liver disease","volume":"2","author":"Kleiner","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.metabol.2020.154291_bb0220","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/hep.21103","article-title":"Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C","volume":"43","author":"Sanyal","year":"2006","journal-title":"Hepatology."},{"issue":"9865","key":"10.1016\/j.metabol.2020.154291_bb0225","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet."},{"issue":"1","key":"10.1016\/j.metabol.2020.154291_bb0230","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/liv.12576","article-title":"Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-analysis","volume":"35","author":"Akhtar","year":"2015","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.metabol.2020.154291_bb0235","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.cgh.2018.10.017","article-title":"Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis","volume":"17","author":"Lee","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.metabol.2020.154291_bb0240","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S2468-1253(18)30077-3","article-title":"Non-alcoholic fatty liver disease and the interface between primary and secondary care","volume":"3","author":"Tsochatzis","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.metabol.2020.154291_bb0245","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jhep.2019.03.033","article-title":"Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease","volume":"71","author":"Srivastava","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2020.154291_bb0250","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/apt.14463","article-title":"Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis in general practice: a cross-sectional study using transient elastography","volume":"47","author":"Harman","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.metabol.2020.154291_bb0255","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-015659","article-title":"Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study","volume":"7","author":"Tanajewski","year":"2017","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.metabol.2020.154291_bb0260","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12876-019-1039-4","article-title":"Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease","volume":"19","author":"Srivastava","year":"2019","journal-title":"BMC Gastroenterol"},{"issue":"11","key":"10.1016\/j.metabol.2020.154291_bb0265","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1111\/liv.14198","article-title":"Referral pathways for patients with NAFLD based on non-invasive fibrosis tests: diagnostic accuracy and cost analysis","volume":"39","author":"Crossan","year":"2019","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.metabol.2020.154291_bb0270","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jhep.2013.08.011","article-title":"Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team","volume":"60","author":"Dyson","year":"2014","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.metabol.2020.154291_bb0275","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/hep.28123","article-title":"Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009","volume":"62","author":"Younossi","year":"2015","journal-title":"Hepatology."},{"issue":"6","key":"10.1016\/j.metabol.2020.154291_bb0280","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","article-title":"Risk of hepatocellular Cancer in patients with non-alcoholic fatty liver disease","volume":"155","author":"Kanwal","year":"2018","journal-title":"Gastroenterology."},{"issue":"3","key":"10.1016\/j.metabol.2020.154291_bb0285","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/hep.28368","article-title":"Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study","volume":"63","author":"Piscaglia","year":"2016","journal-title":"Hepatology."},{"issue":"3","key":"10.1016\/j.metabol.2020.154291_bb0290","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/hep.22734","article-title":"Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis","volume":"49","author":"Paradis","year":"2009","journal-title":"Hepatology."},{"issue":"3","key":"10.1016\/j.metabol.2020.154291_bb0295","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2019.05.008","article-title":"Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification","volume":"71","author":"Ioannou","year":"2019","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.metabol.2020.154291_bb0300","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/TP.0000000000002361","article-title":"Should patients with NAFLD\/NASH be surveyed for HCC?","volume":"103","author":"Reig","year":"2019","journal-title":"Transplantation."},{"issue":"2","key":"10.1016\/j.metabol.2020.154291_bb0305","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jhep.2017.10.006","article-title":"Should we undertake surveillance for HCC in patients with NAFLD?","volume":"68","author":"Younes","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2020.154291_bb0310","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. Electronic address eee. EASL clinical practice guidelines: liver transplantation. J Hepatol 2016;64(2):433\u201385.","DOI":"10.1016\/j.jhep.2015.10.006"},{"issue":"1","key":"10.1016\/j.metabol.2020.154291_bb0315","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/hep.27176","article-title":"Indications for liver transplant and AASLD guidelines","volume":"61","author":"Thapar","year":"2015","journal-title":"Hepatology."},{"issue":"3","key":"10.1016\/j.metabol.2020.154291_bb0320","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/TP.0000000000000945","article-title":"Nonalcoholic Steatohepatitis is the Most rapidly growing indication for simultaneous liver kidney transplantation in the United States","volume":"100","author":"Singal","year":"2016","journal-title":"Transplantation."},{"issue":"6","key":"10.1016\/j.metabol.2020.154291_bb0325","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1002\/hep.26986","article-title":"Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S","volume":"59","author":"Wong","year":"2014","journal-title":"Hepatology."},{"issue":"3","key":"10.1016\/j.metabol.2020.154291_bb0330","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis","volume":"65","author":"Targher","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2020.154291_bb0335","doi-asserted-by":"crossref","first-page":"l5367","DOI":"10.1136\/bmj.l5367","article-title":"Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults","volume":"367","author":"Alexander","year":"2019","journal-title":"BMJ."},{"issue":"5","key":"10.1016\/j.metabol.2020.154291_bb0340","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/hep.25855","article-title":"Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events","volume":"56","author":"Vanwagner","year":"2012","journal-title":"Hepatology."},{"issue":"7","key":"10.1016\/j.metabol.2020.154291_bb0345","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1097\/TP.0000000000002175","article-title":"Cardiovascular disease outcomes related to early stage renal impairment after liver transplantation","volume":"102","author":"VanWagner","year":"2018","journal-title":"Transplantation."},{"issue":"10","key":"10.1016\/j.metabol.2020.154291_bb0350","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/lt.24188","article-title":"Low, rather than high, body mass index confers increased risk for post-liver transplant death and graft loss: risk modulated by model for end-stage liver disease","volume":"21","author":"Bambha","year":"2015","journal-title":"Liver Transpl"},{"issue":"11","key":"10.1016\/j.metabol.2020.154291_bb0355","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/lt.21889","article-title":"Effects of obesity, diabetes, and prior abdominal surgery on resource utilization in liver transplantation: a single-center study","volume":"15","author":"Nair","year":"2009","journal-title":"Liver Transpl"},{"issue":"10","key":"10.1016\/j.metabol.2020.154291_bb0360","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1097\/TP.0000000000001794","article-title":"Liver transplantation in the obese cirrhotic patient","volume":"101","author":"Spengler","year":"2017","journal-title":"Transplantation."},{"issue":"3","key":"10.1016\/j.metabol.2020.154291_bb0365","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1600-6143.2007.02100.x","article-title":"The impact of obesity on long-term outcomes in liver transplant recipients-results of the NIDDK liver transplant database","volume":"8","author":"Leonard","year":"2008","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.metabol.2020.154291_bb0370","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1007\/s10620-014-3469-8","article-title":"Diabetes mellitus, and not obesity, is associated with lower survival following liver transplantation","volume":"60","author":"Wong","year":"2015","journal-title":"Dig Dis Sci"},{"issue":"6","key":"10.1016\/j.metabol.2020.154291_bb0375","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/apt.12881","article-title":"The impact of type 2 diabetes and obesity on the long-term outcomes of more than 85 000 liver transplant recipients in the US","volume":"40","author":"Younossi","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.metabol.2020.154291_bb0380","doi-asserted-by":"crossref","unstructured":"Montano-Loza AJ, Meza-Junco J, Prado CM, Lieffers JR, Baracos VE, Bain VG, et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol. 2012;10(2):166\u201373, 73 e1.","DOI":"10.1016\/j.cgh.2011.08.028"},{"issue":"10","key":"10.1016\/j.metabol.2020.154291_bb0385","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/lt.25598","article-title":"Handgrip strength adds more prognostic value to the model for end-stage liver disease score Than imaging-based measures of muscle mass in men with cirrhosis","volume":"25","author":"Sinclair","year":"2019","journal-title":"Liver Transpl"},{"issue":"2","key":"10.1016\/j.metabol.2020.154291_bb0390","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/jcsm.12039","article-title":"Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis","volume":"7","author":"Montano-Loza","year":"2016","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"10","key":"10.1016\/j.metabol.2020.154291_bb0395","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/lt.23495","article-title":"Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value","volume":"18","author":"Tandon","year":"2012","journal-title":"Liver Transpl"},{"issue":"3","key":"10.1016\/j.metabol.2020.154291_bb0400","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jhep.2018.04.015","article-title":"Low subcutaneous adiposity associates with higher mortality in female patients with cirrhosis","volume":"69","author":"Ebadi","year":"2018","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.metabol.2020.154291_bb0405","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1432-2277.2004.00067.x","article-title":"Weight gain and obesity after liver transplantation","volume":"18","author":"Richards","year":"2005","journal-title":"Transpl Int"},{"issue":"2","key":"10.1016\/j.metabol.2020.154291_bb0410","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/hep.29848","article-title":"Long-term outcomes of patients undergoing simultaneous liver transplantation and sleeve gastrectomy","volume":"68","author":"Zamora-Valdes","year":"2018","journal-title":"Hepatology."},{"issue":"4","key":"10.1016\/j.metabol.2020.154291_bb0415","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1053\/j.gastro.2011.06.061","article-title":"Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States","volume":"141","author":"Charlton","year":"2011","journal-title":"Gastroenterology."},{"issue":"10","key":"10.1016\/j.metabol.2020.154291_bb0420","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1007\/s10620-017-4684-x","article-title":"Liver transplantation for nonalcoholic Steatohepatitis in the US: temporal trends and outcomes","volume":"62","author":"Cholankeril","year":"2017","journal-title":"Dig Dis Sci"},{"issue":"4","key":"10.1016\/j.metabol.2020.154291_bb0425","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/lt.22004","article-title":"Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease","volume":"16","author":"Yalamanchili","year":"2010","journal-title":"Liver Transpl"},{"issue":"9","key":"10.1016\/j.metabol.2020.154291_bb0430","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S2468-1253(19)30181-5","article-title":"Management of metabolic syndrome and cardiovascular risk after liver transplantation","volume":"4","author":"Fatourou","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.metabol.2020.154291_bb0435","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/TP.0b013e31820b6b84","article-title":"NAFLD recurrence in liver transplant recipients","volume":"91","author":"Dureja","year":"2011","journal-title":"Transplantation."},{"issue":"6","key":"10.1016\/j.metabol.2020.154291_bb0440","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.jhep.2016.07.033","article-title":"NAFLD and liver transplantation: current burden and expected challenges","volume":"65","author":"Pais","year":"2016","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.metabol.2020.154291_bb0445","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.1097\/TP.0000000000002916","article-title":"Incidence and risks for nonalcoholic fatty liver disease and Steatohepatitis post-liver transplant: systematic review and meta-analysis","volume":"103","author":"Saeed","year":"2019","journal-title":"Transplantation."},{"issue":"1","key":"10.1016\/j.metabol.2020.154291_bb0450","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2010.01.040","article-title":"Metabolic syndrome and liver transplantation: a review and guide to management","volume":"53","author":"Watt","year":"2010","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.metabol.2020.154291_bb0455","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1097\/TP.0000000000002317","article-title":"Recurrent or De novo allograft Steatosis and Long-term outcomes after liver transplantation","volume":"103","author":"Narayanan","year":"2019","journal-title":"Transplantation."},{"issue":"1","key":"10.1016\/j.metabol.2020.154291_bb0460","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/TP.0000000000002485","article-title":"Management of recurrent and De novo NAFLD\/NASH after liver transplantation","volume":"103","author":"Germani","year":"2019","journal-title":"Transplantation."},{"issue":"1","key":"10.1016\/j.metabol.2020.154291_bb0465","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1432-2277.2012.01576.x","article-title":"Metabolic syndrome and its association with fatty liver disease after orthotopic liver transplantation","volume":"26","author":"Sprinzl","year":"2013","journal-title":"Transpl Int"},{"issue":"4","key":"10.1016\/j.metabol.2020.154291_bb0470","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/lt.21396","article-title":"Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials","volume":"14","author":"Segev","year":"2008","journal-title":"Liver Transpl"},{"issue":"1","key":"10.1016\/j.metabol.2020.154291_bb0475","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/lt.23566","article-title":"Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation","volume":"19","author":"Lucey","year":"2013","journal-title":"Liver Transpl"},{"issue":"9","key":"10.1016\/j.metabol.2020.154291_bb0480","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s11605-015-2832-1","article-title":"Donor hepatic Steatosis and outcome after liver transplantation: a systematic review","volume":"19","author":"Chu","year":"2015","journal-title":"J Gastrointest Surg"},{"issue":"1","key":"10.1016\/j.metabol.2020.154291_bb0485","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/00007890-199101000-00024","article-title":"The predictive value of donor liver biopsies for the development of primary nonfunction after orthotopic liver transplantation","volume":"51","author":"D\u2019Alessandro","year":"1991","journal-title":"Transplantation."},{"issue":"1","key":"10.1016\/j.metabol.2020.154291_bb0490","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/lt.23547","article-title":"Declining liver utilization for transplantation in the United States and the impact of donation after cardiac death","volume":"19","author":"Orman","year":"2013","journal-title":"Liver Transpl"},{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2020.154291_bb0495","first-page":"35","article-title":"Liver Biopsy Results in Potential Donor Evaluation in Living Related Liver Transplant","volume":"16","author":"Ayvazoglu Soy","year":"2018","journal-title":"Exp Clin Transplant"},{"issue":"10","key":"10.1016\/j.metabol.2020.154291_bb0500","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1111\/ajt.14992","article-title":"Ex situ machine perfusion as a tool to recondition steatotic donor livers: troublesome features of fatty livers and the role of defatting therapies. A systematic review","volume":"18","author":"Boteon","year":"2018","journal-title":"Am J Transplant"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049520301554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049520301554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:26:41Z","timestamp":1758428801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049520301554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":100,"alternative-id":["S0026049520301554"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2020.154291","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changing trends of liver transplantation and mortality from non-alcoholic fatty liver disease","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2020.154291","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"154291"}}